Corbus Pharmaceuticals Holdings, INC 10-Q quarterly reports

Corbus Pharmaceuticals reported a wider net loss for Q1 2026 due to increased R&D spending on its oncology and obesity drug candidates, while cash reserves remain sufficient for at least twelve months.

Corbus Pharmaceuticals reports increased R&D expenses and net losses in Q3 2025, while securing significant capital through recent offerings to fund its clinical pipeline.

Corbus Pharmaceuticals reports a significant increase in net loss for Q2 2025, driven by accelerated research and development spending on its oncology and obesity pipeline.

Corbus Pharmaceuticals reports a net loss of $16.98 million for Q1 2025, with increased R&D spending reflecting progress in its oncology and obesity pipeline.

Corbus Pharmaceuticals reports a net loss for Q3 2024, but highlights significant clinical advancements and a strong cash position following recent financing activities.

Corbus Pharmaceuticals reports a significant increase in cash and investments, alongside advancements in their clinical programs for cancer and obesity treatments in the second quarter of 2024.

Corbus Pharmaceuticals' first quarter 2024 results show a reduced net loss compared to the previous year, driven by decreased research and development expenses and a significant capital raise.